Detail akcie Pentixaphar Rg-Unty online

Business Summary: Pentixapharm Holding AG is a Germany-based clinical-stage radiopharmaceutical development company. The Company focuses on the development of radiopharmaceuticals for various therapeutic areas, as well as for the diagnosis and therapy (theranostics) of blood cancer and others. It is also engaged in holding activities and is also involved in the research and development of drugs for hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Pentixapharm Holding AG revenues increased from EUR0K to EUR117K. Net loss applicable to common stockholders increased from EUR49K to EUR12.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Other operating expenses increase from EUR49K to EUR2.2M (expense).